The Latin America Molecular Diagnostics Market is projected to reach $2.50 billion by 2031, at a CAGR of 6.3% from 2024 to 2031. Molecular diagnostics help detect the targeted genetic material in human, viral, and bacterial genomes. Molecular diagnostic tests are increasingly being used in many areas, including infectious diseases, oncology, and clinical genetics. Advancements in molecular diagnostics will continue to improve the accuracy and speed of diagnosis and will become an essential aspect of patient-tailored interventions and therapeutics.
The growth of the Latin America molecular diagnostics market is driven by several factors, including the rising global geriatric population, increasing prevalence of communicable & noncommunicable diseases, technological advancements in molecular diagnostics, and rising healthcare expenditures. Factors such as growing scope in emerging economies, increasing focus on companion diagnostics, and rising popularity of direct-to-consumer (DTC) genetic testing are a few of the opportunities that would help grow the market in the future. A shortage of skilled professionals could be considered a challenge for the Latin America molecular diagnostics market. However, unfavorable regulatory frameworks and high costs of molecular diagnostic tests restrain the growth of the market.
The healthcare landscape is constantly changing due to innovations in medical technologies. In recent years, companies have been focused on developing advanced diagnostic kits that can yield faster results than traditional kits. These advanced kits allow healthcare providers and caregivers to make crucial medical decisions promptly. Several companies have been developing ultra-fast PCR kits to minimize the time required to generate test results.
For instance, in June 2021, Thermo Fisher Scientific, Inc. (U.S.) developed the innovative and portable Accula SARS-CoV-2 Test offering gold-standard Reverse Transcription Polymerase Chain Reaction (RT-PCR) detection of SARS-CoV-2 in a point-of-care format. The test delivers results in 30 minutes, whereas the conventional RT-PCR method takes around 2-3 days to produce results. The product uses a cartridge (lateral flow technology) that can be directly used to analyze samples, unlike conventional RT PCR tests, where nucleic acid extraction takes a significant amount of time.
Integrating digital technologies in clinical and ambulatory settings helps improve doctors’ and physicians’ ability to reach an initial diagnosis. Also, the digitalization of diagnostic services helps document and analyze patient data and test results, which minimizes human error and makes treatment and care pathways more consistent. Hence, an increasing number of patients’ medical histories instantly.
Click here to: Get Free Sample Pages of this Report
Companion molecular diagnostics measures the levels of proteins, genes, or specific mutations to reveal specific and effective therapies for an individual’s condition. Companion diagnostics (CDx) are a form of personalized, stratified, and precision medicine that individualizes a patient’s treatment. CDx has expanded from oncology drugs to multiple therapeutic areas, and the number of combinations has grown significantly over the years. Also, personalized medicine for infectious diseases helps to orient the molecular management of infections. Molecular microbiology offers technologies that can detect and identify microorganisms rapidly.
Determining the pharmacogenomic profiles of patients suffering from infectious diseases provides an additional assessment of the drug metabolizer phenotype and/or of the risk of potential adverse drug interactions. Personalized medicine is thus expected to help develop new therapies and new methods for disease detection.
Among offerings, in 2024, the reagents & kits segment is expected to account for the largest share of the market. Molecular diagnostic kits are widely used by healthcare professionals in hospitals, clinics, and diagnostic laboratories to diagnose and manage various communicable & non-communicable diseases. Recurrent use of assays & kits in the detection of various diseases through molecular diagnostics, rise in product approvals, and technological advancements in molecular techniques contribute to the large market share of this segment.
Among test types, in 2024, the laboratory tests segment is expected to account for the largest share of the market. Lab tests are traditionally used in hospitals and diagnostic centers and are widely accepted. The sample is taken from the patient and sent to the laboratory for processing and testing, where the technicians conduct the processing and testing and create a report for the clinician. The laboratory testing approach for molecular diagnostics has many advantages over other approaches. It has higher accuracy and reliability when compared to point-of-care testing, owing to which the adoption of molecular diagnostics in the lab is more compared to PoC tests.
Among technologies, in 2024, the polymerase chain reaction (PCR) segment is expected to account for the largest share of the molecular diagnostics market in Latin America. PCR allows rapid amplification of a specific segment of DNA. This technology is sensitive and thus helps in the diagnosis of diseases. It is effective for low-number targets and less expensive than other technologies, such as sequencing. Hence, the huge demand for PCR devices further contributes to the segment’s largest share.
Based on application, in 2024, the infectious disease segment is expected to account for the largest share of the molecular diagnostics market in Latin America. Infectious diseases are transmissible or communicable illnesses that spread quickly in some areas and become epidemics. It is crucial to quickly diagnose initial infections and prevent further spread through in vitro diagnosis. The growing prevalence of infectious diseases, the rising funds for infectious disease diagnostic research activities, and the sudden emergence of a pandemic are the factors attributed to the large market share of this segment.
Based on end users, in 2024, the hospitals & clinics segment is expected to account for the largest share of the molecular diagnostics market in Latin America. Factors contributing to the segment’s share include increased hospitalizations due to various diseases, the rise in the geriatric population, and the high prevalence of healthcare-associated infections (HAIs).
In 2024, Brazil is expected to dominate the Latin America molecular diagnostics market. Brazil has a high prevalence of infectious diseases such as hepatitis, dengue, malaria, chikungunya, and zika, which pose significant challenges to the public healthcare system. For this, the Brazilian Ministry of Health, in accordance with the WHO, has outlined a national strategy that aims to expand access to prevention, diagnosis, and treatment of hepatitis C to reduce new infections and mortality. This is expected to offer significant opportunities for the growth of molecular diagnostics in Brazil.
The key players profiled in the Latin America molecular diagnostics market report are Bio-Manguinhos (Brazil), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Hologic, Inc. (U.S.), Illumina, Inc. (U.S.), OmicronLab (Mexico), QIAGEN N.V. (Netherlands), Danaher Corporation (U.S.), Abbott Laboratories (U.S), Agilent Technologies, Inc. (U.S.).
The report includes a competitive landscape based on an extensive assessment of the market based on offering, test type, application, technology, and end user. The report also provides insights into the presence of major market players and their key growth strategies in the last three to four years.
Report Summary:
|
Particular |
Details |
|
Page No |
~220 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2024 |
|
CAGR |
6.3% |
|
Market Size (Value) |
$2.50 billion |
|
Market Size (Volume) |
NA |
|
Segments Covered |
By Offering
By Test Type
By Technology
By Application
By End User
|
|
Countries Covered |
Latin America (Brazil, Mexico, Colombia, Argentina, Chile, Peru, Uruguay, and Rest of Latin America) |
|
Key Companies |
Bio-Manguinhos (Brazil), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Hologic, Inc. (U.S.), Illumina, Inc. (U.S.), OmicronLab (Mexico), QIAGEN N.V. (Netherlands), Danaher Corporation (U.S.), Abbott Laboratories (U.S), Agilent Technologies, Inc. (U.S.). |
This market study covers the market sizes & forecasts of the molecular diagnostics market in Latin America based on offering, test type, technology, application, end user, and geography. This market study also provides the value analysis of various segments and subsegments of the Latin America molecular diagnostics market at country levels.
The Latin America molecular diagnostics market is projected to reach $2.50 billion by 2031, at a CAGR of 6.3% during the forecast period.
The kits & reagents segment is expected to account for the largest share of the market in 2024. Factors such as the need for kits for the growing prevalence of diseases and the growing awareness of early diagnosis among people lead to the largest share of the segment.
The infectious diseases segment is expected to account for the largest share of the market in 2024. Infectious diseases are transmissible or communicable illnesses that spread quickly in some areas and become epidemics. It is crucial to quickly diagnose initial infections and prevent further spread through in vitro diagnosis. The growing prevalence of infectious diseases, the rising funds for infectious disease diagnostic research activities, and the sudden emergence of a pandemic are the factors attributed to the large market share of the segment.
The growth of the Latin America molecular diagnostics market is driven by several factors, including the rising geriatric population, increasing prevalence of communicable & noncommunicable diseases, technological advancements in molecular diagnostics, and rising healthcare expenditures.
Furthermore, the growing scope in emerging economies, increasing focus on companion diagnostics, and the rising popularity of direct-to-consumer (DTC) genetic testing serve as major opportunities for the existing market players and new entrants in the Latin America molecular diagnostics market.
The key players profiled in the Latin America molecular diagnostics market report are Bio-Manguinhos (Brazil), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Hologic, Inc. (U.S.), Illumina, Inc. (U.S.), OmicronLab (Mexico), QIAGEN N.V. (Netherlands), Danaher Corporation (U.S.), Abbott Laboratories (U.S), and Agilent Technologies, Inc. (U.S.).
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumption for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. Rising Geriatric Population
4.2.2. Increasing Prevalence of Communicable & Noncommunicable Diseases
4.2.3 Technological Advancements in Molecular Diagnostics
4.2.4. Rising Healthcare Expenditure
4.3. Restraints
4.3.1. Unfavorable Regulatory Frameworks
4.3.2. High Costs of Molecular Diagnostic Tests
4.4. Opportunities
4.4.1. Growing Scope in Emerging Economies
4.4.2. Increasing Focus on Companion Diagnostics
4.4.3. Rising Popularity of Direct-to-Consumer (DTC) Genetic Testing
4.5. Challenges
4.5.1. Shortage of Skilled Professionals
4.6. Industry & Technology Trends
4.7. Regulatory Scenario
4.8. Pricing Analysis
4.9. Adjacent/Related Market Analysis
5. Latin America Molecular Diagnostics Market Assessment—by Offering
5.1. Overview
5.2. Kits & Reagents
5.3. Instruments
5.4. Software & Services
6. Latin America Molecular Diagnostics Market Assessment—by Test Type
6.1. Overview
6.2. Laboratory Tests
6.3. Point-of-Care (POC) Tests
7. Latin America Molecular Diagnostics Market Assessment—by Technology
7.1. Overview
7.2. Polymerase Chain Reaction (PCR)
7.3. In Situ Hybridization (ISH)
7.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
7.5. Microarrays
7.6. Sequencing
7.7. Mass Spectrometry
7.8. Other Technologies
8. Latin America Molecular Diagnostics Market Assessment—by Application
8.1. Overview
8.2. Infectious Diseases
8.2.1. Respiratory Diseases
8.2.2. Hepatitis
8.2.3. HIV
8.2.4. Chlamydia Trachomatis/Neisseria Gonorrhoeae
8.2.5. Human Papillomavirus (HPV)
8.2.6. Healthcare-Associated Infections (HAIs)
8.2.7. Other Infectious Diseases
8.3. Oncology
8.3.1. Breast Cancer
8.3.2. Colorectal Cancer
8.3.3. Lung Cancer
8.3.4. Prostate Cancer
8.3.5. Lymphoma
8.3.6. Leukemia
8.3.7. Cervical Cancer
8.3.8. Other Cancer Types
8.5. Respiratory Diseases
8.6. Genetic Testing
8.7. Neurological Diseases
8.8. Cardiovascular Diseases
8.9. Other Applications
9. Latin America Molecular Diagnostics Market Assessment—by End User
9.1. Overview
9.2. Hospitals & Clinics
9.3. Diagnostic Laboratories
9.4. Academic & Research Institutes
9.5. Other End Users
10. Latin America Molecular Diagnostics Market Assessment—by Country
10.1. Brazil
10.2. Mexico
10.3. Colombia
10.4. Argentina
10.5. Chile
10.6. Peru
10.7. Uruguay
10.8. Rest of Latin America
11. Competition Analysis
11.1. Overview
11.2. Competitive Benchmarking
11.3. Competitive Dashboard
11.3.1. Market Leaders
11.3.2. Market Differentiators
11.3.3. Vanguards
11.3.4. Emerging Companies
11.4. Market Share Analysis/Market Ranking, By Key Players (2022)
12. Company Profiles (Company Overview, Financial Overview, Product Portfolio, and Strategic Developments)
12.1. Bio-Manguinhos (Brazil)
12.2. F. Hoffmann-La Roche Ltd. (Switzerland)
12.3. Thermo Fisher Scientific Inc. (U.S.)
12.4. Hologic, Inc. (U.S.)
12.5. Illumina, Inc. (U.S.)
12.6. OmicronLab (Mexico)
12.7. QIAGEN N.V. (Netherlands)
12.8. Danaher Corporation (U.S.)
12.9. Abbott Laboratories (U.S.)
12.10. Agilent Technologies, Inc. (U.S.)
( Note: SWOT Analysis of the Top 5 Companies Will Be Provided )
13. Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 Latin America Molecular Diagnostics Market Size, by Offering, 2022–2031 (USD Million)
Table 2 Latin America Molecular Diagnostics Kits & Reagents Market Size, by Country/Region, 2022–2031 (USD Million)
Table 3 Latin Molecular Diagnostics Instruments Market Size, by Country/Region, 2022–2031 (USD Million)
Table 4 Latin America Molecular Diagnostics Software & Services Market Size, by Country/Region, 2022–2031 (USD Million)
Table 5 Latin America Molecular Diagnostics Market Size, by Test Type, 2022–2031 (USD Million)
Table 6 Latin America Molecular Diagnostics for Laboratory Tests, by Country/Region, 2022–2031 (USD Million)
Table 7 Latin America Molecular Diagnostics for PoC Tests, by Country/Region, 2022–2031 (USD Million)
Table 8 Latin America Molecular Diagnostics Market Size, by Technology, 2022–2031 (USD Million)
Table 9 Latin America Molecular Diagnostics for Polymerase Chain Reaction (PCR), by Country/Region, 2022–2031 (USD Million)
Table 10 Latin America Molecular Diagnostics for In Situ Hybridization (ISH), by Country/Region, 2022–2031 (USD Million)
Table 11 Latin America Molecular Diagnostics for Isothermal Nucleic Acid Amplification Technology (INAAT), by Country/Region, 2022–2031 (USD Million)
Table 12 Latin America Molecular Diagnostics for Microarrays, by Country/Region, 2022–2031 (USD Million)
Table 13 Latin America Molecular Diagnostics for Mass Spectrometry, by Country/Region, 2022–2031 (USD Million)
Table 14 Latin America Molecular Diagnostics for Sequencing, by Country/Region, 2022–2031 (USD Million)
Table 15 Latin America Other Technologies Market Size, by Country/Region, 2022–2031 (USD Million)
Table 16 Latin America Molecular Diagnostics Market Size, by Application, 2022–2031 (USD Million)
Table 17 Latin America Molecular Diagnostics Market Size for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 18 Latin America Molecular Diagnostics Market Size for Infectious Diseases Market Size, by Country/Region, 2022–2031 (USD Million)
Table 19 Latin America Infectious Disease Molecular Diagnostics Market Size for Respiratory Diseases, by Country/Region, 2022–2031 (USD Million)
Table 20 Latin America Infectious Disease Molecular Diagnostics Market Size for Hepatitis Testing, by Country/Region, 2022–2031 (USD Million)
Table 21 Latin America Infectious Disease Molecular Diagnostics Market Size for HIV Testing, by Country/Region, 2022–2031 (USD Million)
Table 22 Latin America Infectious Disease Molecular Diagnostics Market Size for CT/NG Testing, by Country/Region, 2022–2031 (USD Million)
Table 23 Latin America Infectious Disease Molecular Diagnostics Market Size for Human papillomavirus (HPV) Testing, by Country/Region, 2022–2031 (USD Million)
Table 24 Latin America Infectious Disease Molecular Diagnostics Market Size for Healthcare-associated Infections (HAIs) Testing, by Country/Region, 2022–2031 (USD Million)
Table 25 Latin America Molecular Diagnostics Market Size for Other Infectious Diseases Testing, by Country/Region, 2022–2031 (USD Million)
Table 26 Latin America Oncology Molecular Diagnostics Market Size, by Type, 2022–2031 (USD Million)
Table 27 Latin America Oncology Molecular Diagnostics Market Size, by Country/Region, 2022–2031 (USD Million)
Table 28 Latin America Oncology Molecular Diagnostics Market Size for Breast Cancer Testing, by Country/Region, 2022–2031 (USD Million)
Table 29 Latin America Oncology Molecular Diagnostics Market Size for Colorectal Cancer Testing, by Country/Region, 2022–2031 (USD Million)
Table 30 Latin America Oncology Molecular Diagnostics Market Size for Lung Cancer Testing, by Country/Region, 2022–2031 (USD Million)
Table 31 Latin America Oncology Molecular Diagnostics Market Size for Prostate Cancer Testing, by Country/Region, 2022–2031 (USD Million)
Table 32 Latin America Oncology Molecular Diagnostics Market Size for Lymphoma Testing, by Country/Region, 2022–2031 (USD Million)
Table 33 Latin America Oncology Molecular Diagnostics Market Size for Leukemia Testing, by Country/Region, 2022–2031 (USD Million)
Table 34 Latin America Oncology Molecular Diagnostics Market Size for Cervical Cancer Testing, by Country/Region, 2022–2031 (USD Million)
Table 35 Latin America Oncology Molecular Diagnostics Market Size for Other Cancer Types Testing, by Country/Region, 2022–2031 (USD Million)
Table 36 Latin America Genetic Testing Molecular Diagnostics Market Size, by Country/Region, 2022–2031 (USD Million)
Table 37 Latin America Neurological Diseases Molecular Diagnostics Market Size, by Country/Region, 2022–2031 (USD Million)
Table 38 Latin America Cardiovascular Diseases Molecular Diagnostics Market Size, by Country/Region, 2022–2031 (USD Million)
Table 39 Latin America Other Applications Molecular Diagnostics Market Size, by Country/Region, 2022–2031 (USD Million)
Table 40 Latin America Molecular Diagnostics Market Size, by End User, 2022–2031 (USD Million)
Table 41 Latin America Molecular Diagnostics Market Size for Hospitals & Clinics, by Country/Region, 2022–2031 (USD Million)
Table 42 Latin America Molecular Diagnostics Market Size for Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 43 Latin America Molecular Diagnostics Market Size for Academic & Research Institutes, by Country/Region, 2022–2031 (USD Million)
Table 44 Latin America Molecular Diagnostics Market Size for Other End Users, by Country/Region, 2022–2031 (USD Million)
Table 45 Latin America Molecular Diagnostics Market Size, by Country/Region, 2022–2031 (USD Million)
Table 46 Latin America: Molecular Diagnostics Market Size, by Offering, 2022–2031 (USD Million)
Table 47 Latin America: Molecular Diagnostics Market Size, by Test Type, 2022–2031 (USD Million)
Table 48 Latin America: Molecular Diagnostics Market Size, by Technology, 2022–2031 (USD Million)
Table 49 Latin America: Molecular Diagnostics Market Size, by Application, 2022–2031 (USD Million)
Table 50 Latin America: Molecular Diagnostics Market Size for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 51 Latin America: Molecular Diagnostics Market Size for Oncology, by Type, 2022–2031 (USD Million)
Table 52 Latin America: Molecular Diagnostics Market Size, by End User, 2022–2031 (USD Million)
Table 53 Brazil: Molecular Diagnostics Market Size, by Offering, 2022–2031 (USD Million)
Table 54 Brazil: Molecular Diagnostics Market Size, by Test Type, 2022–2031 (USD Million)
Table 55 Brazil: Molecular Diagnostics Market Size, by Technology, 2022–2031 (USD Million)
Table 56 Brazil: Molecular Diagnostics Market Size, by Application, 2022–2031 (USD Million)
Table 57 Brazil: Molecular Diagnostics Market Size for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 58 Brazil: Molecular Diagnostics Market Size for Oncology, by Type, 2022–2031 (USD Million)
Table 59 Brazil: Molecular Diagnostics Market Size, by End User, 2022–2031 (USD Million)
Table 60 Mexico: Molecular Diagnostics Market Size, by Offering, 2022–2031 (USD Million)
Table 61 Mexico: Molecular Diagnostics Market Size, by Test Type, 2022–2031 (USD Million)
Table 62 Mexico: Molecular Diagnostics Market Size, by Technology, 2022–2031 (USD Million)
Table 63 Mexico: Molecular Diagnostics Market Size, by Application, 2022–2031 (USD Million)
Table 64 Mexico: Molecular Diagnostics Market Size for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 65 Mexico: Molecular Diagnostics Market Size for Oncology, by Type, 2022–2031 (USD Million)
Table 66 Mexico: Molecular Diagnostics Market Size, by End User, 2022–2031 (USD Million)
Table 67 Colombia: Molecular Diagnostics Market Size, by Offering, 2022–2031 (USD Million)
Table 68 Colombia: Molecular Diagnostics Market Size, by Test Type, 2022–2031 (USD Million)
Table 69 Colombia: Molecular Diagnostics Market Size, by Technology, 2022–2031 (USD Million)
Table 70 Colombia: Molecular Diagnostics Market Size, by Application, 2022–2031 (USD Million)
Table 71 Colombia: Molecular Diagnostics Market Size for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 72 Colombia: Molecular Diagnostics Market Size for Oncology, by Type, 2022–2031 (USD Million)
Table 73 Colombia: Molecular Diagnostics Market Size, by End User, 2022–2031 (USD Million)
Table 74 Argentina: Molecular Diagnostics Market Size, by Offering, 2022–2031 (USD Million)
Table 75 Argentina: Molecular Diagnostics Market Size, by Test Type, 2022–2031 (USD Million)
Table 76 Argentina: Molecular Diagnostics Market Size, by Technology, 2022–2031 (USD Million)
Table 77 Argentina: Molecular Diagnostics Market Size, by Application, 2022–2031 (USD Million)
Table 78 Argentina: Molecular Diagnostics Market Size for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 79 Argentina: Molecular Diagnostics Market Size for Oncology, by Type, 2022–2031 (USD Million)
Table 80 Argentina: Molecular Diagnostics Market Size, by End User, 2022–2031 (USD Million)
Table 81 Chile: Molecular Diagnostics Market Size, by Offering, 2022–2031 (USD Million)
Table 82 Chile: Molecular Diagnostics Market Size, by Test Type, 2022–2031 (USD Million)
Table 83 Chile: Molecular Diagnostics Market Size, by Technology, 2022–2031 (USD Million)
Table 84 Chile: Molecular Diagnostics Market Size, by Application, 2022–2031 (USD Million)
Table 85 Chile: Molecular Diagnostics Market Size for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 86 Chile: Molecular Diagnostics Market Size for Oncology, by Type, 2022–2031 (USD Million)
Table 87 Chile: Molecular Diagnostics Market Size, by End User, 2022–2031 (USD Million)
Table 88 Peru: Molecular Diagnostics Market Size, by Offering, 2022–2031 (USD Million)
Table 89 Peru: Molecular Diagnostics Market Size, by Test Type, 2022–2031 (USD Million)
Table 90 Peru: Molecular Diagnostics Market Size, by Technology, 2022–2031 (USD Million)
Table 91 Peru: Molecular Diagnostics Market Size, by Application, 2022–2031 (USD Million)
Table 92 Peru: Molecular Diagnostics Market Size for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 93 Peru: Molecular Diagnostics Market Size for Oncology, by Type, 2022–2031 (USD Million)
Table 94 Peru: Molecular Diagnostics Market Size, by End User, 2022–2031 (USD Million)
Table 95 Uruguay: Molecular Diagnostics Market Size, by Offering, 2022–2031 (USD Million)
Table 96 Uruguay: Molecular Diagnostics Market Size, by Test Type, 2022–2031 (USD Million)
Table 97 Uruguay: Molecular Diagnostics Market Size, by Technology, 2022–2031 (USD Million)
Table 98 Uruguay: Molecular Diagnostics Market Size, by Application, 2022–2031 (USD Million)
Table 99 Uruguay: Molecular Diagnostics Market Size for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 100 Uruguay: Molecular Diagnostics Market Size for Oncology, by Type, 2022–2031 (USD Million)
Table 101 Uruguay: Molecular Diagnostics Market Size, by End User, 2022–2031 (USD Million)
Table 102 Rest of Latin America: Molecular Diagnostics Market Size, by Offering, 2022–2031 (USD Million)
Table 103 Rest of Latin America: Molecular Diagnostics Market Size, by Test Type, 2022–2031 (USD Million)
Table 104 Rest of Latin America: Molecular Diagnostics Market Size, by Technology, 2022–2031 (USD Million)
Table 105 Rest of Latin America: Molecular Diagnostics Market Size, by Application, 2022–2031 (USD Million)
Table 106 Rest of Latin America: Molecular Diagnostics Market Size for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 107 Rest of Latin America: Molecular Diagnostics Market Size for Oncology, by Type, 2022–2031 (USD Million)
Table 108 Rest of Latin America: Molecular Diagnostics Market Size, by End User, 2022–2031 (USD Million)
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for the Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Latin America Molecular Diagnostics Market, by Offering, 2022–2031 (USD Million)
Figure 8 Latin America Molecular Diagnostics Market, by Test Type, 2022–2031 (USD Million)
Figure 9 Latin America Molecular Diagnostics Market, by Technology, 2022–2031 (USD Million)
Figure 10 Latin America Molecular Diagnostics Market, by Application, 2022–2031 (USD Million)
Figure 11 Latin America Molecular Diagnostics Market, by End User, 2022–2031 (USD Million)
Figure 12 Latin America Molecular Diagnostics Market, by Country/Region
Figure 13 Market Dynamics: Latin America Molecular Diagnostics Market
Figure 14 Latin America Molecular Diagnostics Market, by Offering, 2024 Vs. 2031 (USD Million)
Figure 15 Latin America Molecular Diagnostics Market, by Test Type, 2024 Vs. 2031 (USD Million)
Figure 16 Latin America Molecular Diagnostics Market, by Technology, 2024 Vs. 2031 (USD Million)
Figure 17 Latin America Molecular Diagnostics Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 18 Latin America Molecular Diagnostics Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 19 Latin America Molecular Diagnostics Market, by Country/Region, 2024 Vs. 2031 (USD Million)
Figure 20 Latin America Molecular Diagnostics Market Snapshot
Figure 21 Key Growth Strategies Adopted by Leading Players (2020–2023)
Figure 22 Latin America Molecular Diagnostics Market: Competitive Benchmarking, by Type
Figure 23 Latin America Molecular Diagnostics Market: Competitive Dashboard
Figure 24 Latin America Molecular Diagnostics Market: Market Share Analysis (2023)
Figure 25 F. Hoffmann-La Roche Ltd.: Financial Overview (2022)
Figure 26 Thermo Fisher Scientific, Inc.: Financial Overview (2022)
Figure 27 Hologic, Inc.: Financial Overview (2022)
Figure 28 Illumina, Inc.: Financial Overview (2022)
Figure 29 QIAGEN N.V.: Financial Overview (2022)
Figure 30 Danaher Corporation: Financial Overview (2022)
Figure 31 Abbott Laboratories: Financial Overview (2022)
Figure 32 Agilent Technologies, Inc.: Financial Overview (2023)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Nov-2023
Published Date: Nov-2023
Published Date: Sep-2023
Published Date: Aug-2023
